Skip to main content

Table 2 Univariate and multivariate analyses of risk factors with RFS and OS in ICC patients

From: Investigating effects of preoperative inflammatory biomarkers on predicting survival outcomes of intrahepatic cholangiocarcinoma after curative resection

Variables

RFS

OS

HR (95%CI)

P value

HR (95%CI)

P value

Univariate analyses

 Age (years) (> 60 vs. ≤ 60)

0.670 (0.440, 1.018)

0.061

0.794 (0.514, 1.226)

0.298

 Gender (male vs. female)

0.899 (0.603, 1.341)

0.603

0.763 (0.502, 1.161)

0.207

 Tumor size (cm)

1.126 (1.053, 1.204)

0.001

1.107 (1.035, 1.186)

0.003

 Number of tumors (multiple vs. single)

1.797 (1.168, 2.763)

0.008

1.936 (1.246, 3.008)

0.003

 AJCC tumor stage (III vs. I and II)

1.726 (1.135, 2.624)

0.011

1.960 (1.250, 3.074)

0.003

 Lymph node metastasis (yes vs. no)

1.881 (1.243, 2.848)

0.003

2.197 (1.430, 3.376)

< 0.001

 Vascular invasion (yes vs. no)

1.558 (1.041, 2.332)

0.031

1.478 (0.972, 2.248)

0.068

 Tumor differentiation (poor to undifferentiated vs. well to moderate)

2.173 (1.389, 3.401)

0.001

1.971 (1.222, 3.179)

0.005

 ALT (U/L)

0.998 (0.994, 1.001)

0.195

0.999 (0.995, 1.003)

0.570

 AST (U/L)

0.996 (0.990, 1.003)

0.273

0.999 (0.993, 1.005)

0.815

 CEA (ng/ml)

1.020 (1.008, 1.032)

0.001

1.027 (1.015, 1.040)

< 0.001

 CA19-9 (U/ml)

1.002 (1.001, 1.002)

< 0.001

1.002 (1.001, 1.003)

< 0.001

 CA242 (U/ml)

1.005 (1.003, 1.007)

< 0.001

1.005 (1.003, 1.007)

< 0.001

 NLR

1.018 (0.947, 1.096)

0.625

1.033 (0.960, 1.112)

0.387

 PLR

1.003 (1.000, 1.005)

0.021

1.003 (1.001, 1.006)

0.011

 LMR

1.039 (0.943, 1.146)

0.435

1.019 (0.903, 1.151)

0.757

 SII (SII-low group vs. SII-high group)

2.352 (1.519, 3.641)

< 0.001

2.340 (1.484, 3.689)

< 0.001

 Albumin (g/L)

0.979 (0.936, 1.023)

0.347

0.969 (0.924, 1.017)

0.203

 Child-Pugh score (B vs. A)

0.996 (0.564, 1.757)

0.988

1.286 (0.725, 2.279)

0.389

Multivariate analyses

 Tumor size (cm)

1.030 (0.953, 1.113)

0.456

0.976 (0.899, 1.060)

0.563

 Number of tumors (multiple vs. single)

1.849 (1.168, 2.928)

0.009

2.017 (1.274, 3.192)

0.003

 AJCC tumor stage (III vs. I and II)

1.599 (1.018, 2.511)

0.042

1.982 (1.207, 3.255)

0.007

 Tumor differentiation (poor to undifferentiated vs. well to moderate)

2.355 (1.444, 3.840)

0.001

1.865 (1.093, 3.182)

0.022

 CEA (ng/ml)

1.022 (1.008, 1.037)

0.003

1.033 (1.017, 1.049)

< 0.001

 CA19-9 (U/ml)

1.001 (1.000, 1.002)

0.034

1.002 (1.001, 1.003)

0.001

 CA242 (U/ml)

1.001 (0.998, 1.004)

0.552

0.999 (0.996, 1.003)

0.712

 PLR

0.998 (0.995, 1.002)

0.327

0.998 (0.995, 1.002)

0.316

 SII (SII-high group vs. SII-low group)

2.368 (1.279, 4.386)

0.006

2.454 (1.278, 4.712)

0.007

  1. HR hazard ratio, CI confidence interval, ICC intrahepatic cholangiocarcinoma, RFS recurrence-free survival, OS overall survival, AJCC American Joint Committee on Cancer, ALT alanine aminotransferase, AST aspartate aminotransferase, CEA carcinoembryonic antigen, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, LMR lymphocyte-to-monocyte ratio, SII systemic immune-inflammation index